Provided by Tiger Trade Technology Pte. Ltd.

Natera

326.14
-4.1700-1.26%
Pre-market: 330.554.41+1.35%07:00 EDT
Volume:1.07M
Turnover:349.46M
Market Cap:46.71B
PE:-237.56
High:331.19
Open:324.92
Low:320.65
Close:330.31
52wk High:343.18
52wk Low:157.43
Shares:143.22M
Float Shares:139.00M
Volume Ratio:1.20
T/O Rate:0.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3729
EPS(LYR):-1.5269
ROE:-12.54%
ROA:-8.08%
PB:25.64
PE(LYR):-213.60

Loading ...

Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jul 10

Natera Shares Gain 2.8% After EU Certification for Cancer Test

THOMSON REUTERS
·
Jul 09

How New Signatera Colorectal Data and Trial Deals Could Shape Natera’s (NTRA) Long-Term Narrative

Simply Wall St.
·
Jul 09

Natera price target raised to $310 from $250 at Morgan Stanley

TIPRANKS
·
Jul 09

Natera Announces Ivdr Certification for Signatera™ Across Multiple Cancers

THOMSON REUTERS
·
Jul 09

Natera’s Signatera MRD Test Wins EU IVDR Certification for Multiple Cancers

Reuters
·
Jul 09

Natera Executive Chairman Matthew Rabinowitz Reports Disposal of 1,000 Common Shares Worth $280,000

Reuters
·
Jul 09

Natera President, Clinical Diagnostics Solomon Moshkevich Disposes of USD 819,636 in Common Shares

Reuters
·
Jul 07

Natera Announces Board Resignation Amid Governance Transition

TIPRANKS
·
Jul 07

Natera Director Monica Bertagnolli Resigns to Take National Academy of Medicine Role

Reuters
·
Jul 07

Natera is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Jul 07

Natera Says Colorectal Liver Metastasis Test Identifies Patients Who Benefit From Chemotherapy

MT Newswires Live
·
Jul 06

Natera Signatera MRD Test Data in JAMA Oncology Links Chemo to Overall Survival Gain in Resected Metastatic Colorectal Cancer

Reuters
·
Jul 06

Natera (NTRA) Lands New Trial Partnerships, Is The Upside Already Priced In?

Simply Wall St.
·
Jul 03

When Multi-cancer Blood Screens Could Finally Take Off

Dow Jones
·
Jul 02

Movement Alert|Natera Falls 5.1% in After-Hours Trading, Trading at $270.25

Market Focus
·
Jul 01

Natera is Maintained at Buy by Guggenheim

Dow Jones
·
Jun 29

Natera, Aveta Biomics announce strategic partnership

TIPRANKS
·
Jun 29

Natera Partners with Aveta Biomics on Phase 3 Apg-157 Head and Neck Cancer Trial

Reuters
·
Jun 29

Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of Apg-157 in Head and Neck Cancer

THOMSON REUTERS
·
Jun 29